Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
Want to see IN:SAKAR full AI Analyst Report?
Top Page
Sakar Healthcare Ltd
(SAKAR)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹684.00
▲(68.24% Upside)
Action:UpgradedDate:04/14/26
The score is driven primarily by solid financial performance (strong revenue growth and improving operating efficiency, tempered by a sharp gross margin decline and still-negative free cash flow) and strong bullish technical momentum (price well above key moving averages with positive MACD). Valuation is neutral-to-slightly supportive at a mid-range P/E, with no dividend yield data to add support.
Positive Factors
Consistent Revenue Growth
Sakar's mid-teens top-line growth across recent years shows durable demand for its formulations and successful market execution. Persisting revenue expansion supports scale benefits, broader customer reach and underpins long-term investment capacity in manufacturing and distribution.
Negative Factors
Sharp Gross Margin Decline
A halving of gross margin suggests structural pressure from product mix shifts, pricing, input costs or channel changes. If persistent, lower gross margins compress operating leverage, reduce cash generation and require either price recovery or cost restructuring to restore historical profitability levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sakar's mid-teens top-line growth across recent years shows durable demand for its formulations and successful market execution. Persisting revenue expansion supports scale benefits, broader customer reach and underpins long-term investment capacity in manufacturing and distribution.
Read all positive factors
Sakar Healthcare Ltd (SAKAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹13.81B
Dividend YieldN/A
Average Volume (3M)19.08K
Price to Earnings (P/E)22.2
Beta (1Y)0.68
Revenue Growth35.49%
EPS Growth67.03%
CountryIN
Employees325
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.61
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.79
Price to Sales (P/S)2.88
P/FCF Ratio-37.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹605.00Price Target Upside48.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sakar Healthcare Ltd Business Overview & Revenue Model
Company Description
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoule...
How the Company Makes Money
Sakar Healthcare primarily makes money by selling pharmaceutical finished-dosage formulations. Its revenue is generated from (1) branded and/or generic formulations sold into the Indian market via distributors/stockists and channel partners, and (...
Sakar Healthcare Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 1.78B | 1.54B | 1.33B | 1.28B | 947.39M |
| Gross Profit | 719.02M | 427.91M | 699.59M | 598.12M | 534.12M | 432.46M |
| EBITDA | 535.80M | 509.44M | 393.27M | 378.12M | 315.72M | 237.73M |
| Net Income | 195.05M | 175.02M | 116.71M | 127.59M | 152.43M | 106.83M |
Balance Sheet | ||||||
| Total Assets | 4.49B | 4.15B | 3.89B | 3.36B | 2.68B | 1.78B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16M | 3.09M | 4.66M | 35.23M | 71.36M | 824.65K |
| Total Debt | 718.62M | 749.55M | 793.52M | 1.19B | 928.62M | 425.97M |
| Total Liabilities | 1.45B | 1.30B | 1.26B | 1.63B | 1.40B | 793.40M |
| Stockholders Equity | 3.03B | 2.85B | 2.62B | 1.73B | 1.27B | 984.52M |
Cash Flow | ||||||
| Free Cash Flow | 31.88M | -135.52M | -350.93M | -468.81M | -618.33M | -209.69M |
| Operating Cash Flow | 305.87M | 187.31M | 244.67M | 353.14M | 356.99M | 145.77M |
| Investing Cash Flow | -274.00M | -307.09M | -515.39M | -743.77M | -903.72M | -468.33M |
| Financing Cash Flow | -32.81M | -34.79M | 274.45M | 410.96M | 320.33M | 320.33M |
Sakar Healthcare Ltd Technical Analysis
Positive
406.55
Price Trends
511.48
Positive
454.36
Positive
403.50
Positive
Market Momentum
23.52
Negative
63.18
Neutral
65.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Positive. The current price of 406.55 is below the 20-day moving average (MA) of 544.10, below the 50-day MA of 511.48, and above the 200-day MA of 403.50, indicating a bullish trend. The MACD of 23.52 indicates Negative momentum. The RSI at 63.18 is Neutral, neither overbought nor oversold. The STOCH value of 65.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SAKAR.
Sakar Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹12.68B | 10.01 | ― | ― | 7.99% | 119.03% | |
71 Outperform | ₹13.81B | 22.21 | ― | ― | 35.49% | 67.03% | |
62 Neutral | ₹5.27B | 34.53 | ― | ― | 13.85% | 32.02% | |
56 Neutral | ₹11.90B | 18.86 | ― | ― | 32.95% | -10.44% | |
55 Neutral | ₹3.48B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
52 Neutral | ₹2.64B | 7.63 | ― | ― | -57.41% | -2188.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SAKAR
Sakar Healthcare Ltd
626.25
334.88
114.93%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
134.65
58.45
76.71%
IN:KILITCH
Kilitch Drugs (India) Limited
154.20
-41.84
-21.34%
IN:MEDICAMEQ
Medicamen Biotech Limited
253.20
-183.39
-42.01%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.51
-9.71
-43.70%
IN:VENUSREM
Venus Remedies Limited
938.05
626.90
201.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.